This is the second of a series of articles focusing on some of the newand emerging biotechnology companies that gave presentations at the Biopartnering Europe conference held October 6-7 in London, UK.
Orchid Biocomputer Inc
Orchid is a joint venture set up between SmithKline Beecham and the Sarnoff Corporation in September 1995 with the objective of developing high-through-put systems for the rapid synthesis and screening of molecules for discovery, with its lead program being to design a microchip the size of a business card, called Chemtel. It is developing a chip that is capable of synthesizing and assaying 10,000 combinatorial chemistry compounds, and expects it to be available in early 1999.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze